Literature DB >> 10446448

Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity.

I Zborovskaya1, A Gasparian, A Karseladze, I Elcheva, E Trofimova, K Driouch, M Trassard, A Tatosyan, R Lidereau.   

Abstract

Loss of heterozygosity (LOH) affects a number of chromosome regions in ovarian cancer, pointing to the possible involvement of tumour-suppressor genes in ovarian tumorigenesis. We performed comparative analysis of allelic loss at 6 frequently affected chromosome regions in a panel of 53 benign, borderline and malignant ovarian tumours. Precursor lesions could provide evidence that an accumulation of genetic events is required for normal ovarian epithelium to generate malignant tumours. LOH on chromosome 1p was relatively common in benign, borderline and malignant tumours, while at 11p and 7q it was observed not only in invasive but also in borderline tumours. Moreover, 17q and 18q were affected mainly in advanced malignant tumours and revealed a high frequency of clonal intratumoral heterogeneity. We encountered different spectra of genetic alterations in primary tumours and their metastasis, which may be the results of intratumoral heterogeneity leading to dissemination in only some sub-clones. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446448     DOI: 10.1002/(sici)1097-0215(19990909)82:6<822::aid-ijc9>3.0.co;2-i

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

Authors:  H Lassus; R Salovaara; L A Aaltonen; R Butzow
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 3.  Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.

Authors:  Patriciu Achimas-Cadariu; Paul Kubelac; Alexandru Irimie; Ioana Berindan-Neagoe; Frank Rühli
Journal:  J Ovarian Res       Date:  2022-06-03       Impact factor: 5.506

Review 4.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

5.  Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer.

Authors:  Gabriele Mittermeyer; Katharina Malinowsky; Christian Beese; Heinz Höfler; Barbara Schmalfeldt; Karl-Friedrich Becker; Stefanie Avril
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

6.  The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.

Authors:  Huimin Bai; Haixia Li; Weihua Li; Ting Gui; Jiaxin Yang; Dongyan Cao; Keng Shen
Journal:  Oncotarget       Date:  2015-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.